Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

NQPC-10 END-OF-LIFE PHASE OF GLIOBLASTOMA

View through CrossRef
Abstract BACKGROUND Despite aggressive treatment with surgery and chemo-radiation therapy, it is difficult to cure patients with glioblastoma (GBM). The end-of-life (EOL) phase of patients with GBM, and related problems, have not yet been adequately studied. Most cancer patients died in the hospital (84%) in 2017, but the Japanese government has recommended palliative home-care and the number of deaths at home has recently been increasing. This study explores the current situation of EOL care for GBM patients in our hospital. METHODS We retrospectively examined the clinical course and EOL phase of 166 consecutive patients who were treated in our hospital between 2010 and 2017. RESULT In total, 107 patients died; 28 (26%) at home, 25 (23%) in hospice care, 9(9%) in nursing homes, 21(20%) in long-term care hospitals (LTCH), 13(12%) in our hospital, and 11(10%) in other neurosurgical hospitals. The median survival time and length of EOL phase for patients who died at home were 596 and 77 days; 469 and 103 days in hospice care; 528 days and 149 days in LTCH; 388 days and 52 days in our hospital; 802 and 91 days in other neurosurgical hospital; and 565 days and 55 days in nursing homes, respectively. The KPS of patients who transferred to LTCH or was started palliative care in other neurological hospital was 60. That of other patients was 50.The patients who died at home entered deep coma in the last 3.5 days (n=24) of life and could not take oral feeds for 7 days (n=26). CONCLUSION According to cancer patient study, the home-based palliative time of longer prognosis group were 59 days. EOL phase of GBM may be longer than other cancer. We must consider the problems of the EOL phase and improve the quality of EOL care.
Title: NQPC-10 END-OF-LIFE PHASE OF GLIOBLASTOMA
Description:
Abstract BACKGROUND Despite aggressive treatment with surgery and chemo-radiation therapy, it is difficult to cure patients with glioblastoma (GBM).
The end-of-life (EOL) phase of patients with GBM, and related problems, have not yet been adequately studied.
Most cancer patients died in the hospital (84%) in 2017, but the Japanese government has recommended palliative home-care and the number of deaths at home has recently been increasing.
This study explores the current situation of EOL care for GBM patients in our hospital.
METHODS We retrospectively examined the clinical course and EOL phase of 166 consecutive patients who were treated in our hospital between 2010 and 2017.
RESULT In total, 107 patients died; 28 (26%) at home, 25 (23%) in hospice care, 9(9%) in nursing homes, 21(20%) in long-term care hospitals (LTCH), 13(12%) in our hospital, and 11(10%) in other neurosurgical hospitals.
The median survival time and length of EOL phase for patients who died at home were 596 and 77 days; 469 and 103 days in hospice care; 528 days and 149 days in LTCH; 388 days and 52 days in our hospital; 802 and 91 days in other neurosurgical hospital; and 565 days and 55 days in nursing homes, respectively.
The KPS of patients who transferred to LTCH or was started palliative care in other neurological hospital was 60.
That of other patients was 50.
The patients who died at home entered deep coma in the last 3.
5 days (n=24) of life and could not take oral feeds for 7 days (n=26).
CONCLUSION According to cancer patient study, the home-based palliative time of longer prognosis group were 59 days.
EOL phase of GBM may be longer than other cancer.
We must consider the problems of the EOL phase and improve the quality of EOL care.

Related Results

A Flexibly Conditional Screening Approach via a Nonparametric Quantile Partial Correlation
A Flexibly Conditional Screening Approach via a Nonparametric Quantile Partial Correlation
Considering the influence of conditional variables is crucial to statistical modeling, ignoring this may lead to misleading results. Recently, Ma, Li and Tsai proposed the quantile...
BCAT1 regulates glioblastoma cell plasticity and contributes to immunosuppression
BCAT1 regulates glioblastoma cell plasticity and contributes to immunosuppression
Abstract Glioblastoma is the most common malignant brain tumor in adults. Cellular plasticity and the poorly differentiated features result in a ...
Abstract 1842: Drug repurposing screen reveals glioblastoma cell line susceptibility to statins
Abstract 1842: Drug repurposing screen reveals glioblastoma cell line susceptibility to statins
Abstract Background: The standard therapy for glioblastoma patients is tumor resection followed by radiotherapy and temozolomide chemotherapy. Although glioblastoma ...
P10.36.B ROLE OF AMPK IN GLIOBLASTOMA BIOENERGETICS
P10.36.B ROLE OF AMPK IN GLIOBLASTOMA BIOENERGETICS
Abstract BACKGROUND Glioblastoma is the most prevalent and aggressive primary brain tumor. AMP-activated kinase (AMPK), the main...
Abstract 2205: Exploring the presence and role of causative viruses in glioblastoma using a multi-omics approach
Abstract 2205: Exploring the presence and role of causative viruses in glioblastoma using a multi-omics approach
Abstract Glioblastoma (GB) is the most aggressive brain cancer with a poor survival rate. While molecular markers have been established to improve treatment response...
Clinical Insights and Management Strategies for Gliosarcoma: A Case Report
Clinical Insights and Management Strategies for Gliosarcoma: A Case Report
Abstract Introduction: Gliosarcoma (GSM) is a rare, aggressive primary CNS tumor and a histopathological variant of glioblastoma, characterized by both glial and sarcomatou...
Abstract 2200: The mesenchymal state drives stemness and limits differentiation in glioblastoma.
Abstract 2200: The mesenchymal state drives stemness and limits differentiation in glioblastoma.
Abstract Glioblastoma is a highly heterogeneous and lethal brain cancer with limited therapeutic options. Recent single-cell omics studies have emphasized the imp...
A Comprehensive Review of miRNAs and Their Epigenetic Effects in Glioblastoma
A Comprehensive Review of miRNAs and Their Epigenetic Effects in Glioblastoma
Glioblastoma is the most aggressive form of brain tumor originating from glial cells with a maximum life expectancy of 14.6 months. Despite the establishment of multiple promising ...

Back to Top